Review for 10.1186/s12876-020-01584-6 (2021)

Reviewer’s report
Title: 
Differential gene expression analysis of dasatinib-induced colitis in a
patient with chronic myeloid leukemia followed for 3 years: a case report
Version: 
0 
Date: 
11 Oct 2020
Reviewer's report:
The authors describe a case of dasatinib-induced colitis during treatment for
CML .
The patient was asymptomatic , and improvement of colitis was observed after a
dose reduction of dasatinib for mild pleural effusion .
The authors could include these points in the discussion :
1)dasatinib-induced colitis seems to be not an infrequent event and and part of
patients are asymptomatic but in 
all cases there is a positivity for fecal occult
blood . Could be useful execution of fecal occult blood test for patients treated
with dasatinib in order to detect colitis ?
2)The patient obtained an improvement of colitis after a dose reduction of
dasatinib that was caused by a mild pleural effusion . Dasatinib-induced colitis
seems to be dose related . Actually the goal of therapy in CML for many patients
is the discontinuation of treatment that is safe and feasible in half of cases (
Imatinib discontinuation in chronic myeloid leukaemia patients with
undetectable BCR-ABL transcript level: A systematic review and a meta-
analysis. Campiotti L, Suter MB, Guasti L, et al. Eur J Cancer. 2017 May;77:48-
56. ). A correct conduction of therapy is the cornerstone to obtain a 
stable deep
molecular remission that is the most important requirement to enter in a program
of therapy discontinuation . The authors could discuss the role of dose reduction
of dasatinib versus a possibile treatment of colitis with mesalazine or budesonide
in asymptomatic patients .
Publons Reviewer Recognition
. Springer Nature can send verification of this
review directly to Publons (a subsidiary of Clarivate Analytics). If you would
like to take advantage of this service, please click on the “Yes” option below.
Your name, email address, title of the reviewed manuscript, name of the journal,
and date of your review submission (the “Review Data”) will then be transmitted
to Publons upon publication of the manuscript. If you have already registered at
Publons, they will notify you of the receipt of this review and update your profile
as per your settings and their policy. If you are not registered with Publons, you
will receive an email from them asking you to register in order for them to be
able to recognize your review on your new profile page. Publons may use the
Review Data to generate derivative metadata for the benefit of Publons and you
as a reviewer, carefully considering the sensitivity of such information. For
example, Publons may verify your record as a reviewer by updating your profile
published on its webservice if you have registered for such service or help
editors to identify candidate reviewers. Please find the details of processing in
Publons’ privacy policy 
https://publons.com/about/terms
Yes
Declaration of competing interests
Please complete a declaration of competing interests, considering the following
questions:
1
. 
Have you in the past five years received reimbursements, fees, funding, or
salary from an organisation that may in any way gain or lose financially
from the publication of this manuscript, either now or in the future?
2
. 
Do you hold any stocks or shares in an organisation that may in any way
gain or lose financially from the publication of this manuscript, either now
or in the future?
3
. 
Do you hold or are you currently applying for any patents relating to the
content of the manuscript?
4
. 
Have you received reimbursements, fees, funding, or salary from an
organization that holds or has applied for patents relating to the content of
the manuscript?
5
. 
Do you have any other financial competing interests?
6
. 
Do you have any non-financial competing interests in relation to this
paper?
If you can answer no to all of the above, write 'I declare that I have no competing
interests' below. If your reply is yes to any, please give details below.
I declare that I have no competing interests
Reviewer Publication Consent.
 I agree for my report to be made available
under an Open Access Creative Commons CC-BY License (
http://creativecommons.org/licenses/by/4.0
) if this manuscript is accepted for
publication. Any comments that I do not wish to be included in the published
report have been included as confidential comments to the editor, which will not
be published.
If you are not happy for us to publish this report, please contact the editorial
office before completing the review.
If you wish, you can include your name in your published report. Please note
you must decide whether to include your name at the start of the process and
confirm this decision whenever prompted. If you change your decision later, we
will not be able to publish your name.
I agree to the terms of the CC-BY 4.0 license; please 
do not
 publish my name
with my report. (default)
Is the study design appropriate to answer the research question (including the use
of appropriate controls), and are the conclusions supported by the evidence
presented?
Yes
Are the methods sufficiently described to allow the study to be repeated?
Yes
Is the use of statistics and treatment of uncertainties appropriate?
Yes
Is the presentation of the work clear?
Yes
Are the images in this manuscript (including electrophoretic gels and blots) free
from apparent manipulation?
Yes